Loading clinical trials...
Loading clinical trials...
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Conditions
Interventions
PTC923
Placebo
Locations
43
United States
Stanford University Center for Academic Medicine
Stanford, California, United States
University of Colorado and the Children's Hospital CO
Aurora, Colorado, United States
UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism
Gainesville, Florida, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, United States
Start Date
September 30, 2021
Primary Completion Date
April 3, 2023
Completion Date
May 3, 2023
Last Updated
January 10, 2024
NCT06628128
NCT06971731
NCT05579548
NCT06560736
NCT06332807
NCT06780332
Lead Sponsor
PTC Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions